ArticleJCO precision oncology2026
Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.
Erratum issuedAbstract read
In one paragraph
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
57 authors.
Hannah E HartleyWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom.ORCID 0009-0006-3613-0845
Fang Chyi FongWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom.ORCID 0000-0001-7771-3840
Alem S GabrielWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Louise K StevensonWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Emily BeckettWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom.ORCID 0009-0007-6484-4623
Lisa M AllinsonWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom.ORCID 0000-0002-8957-6609
Angharad GoodmanNewcastle Genetics Laboratory, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom.ORCID 0000-0002-3010-5757
Aaron PottsNewcastle Genetics Laboratory, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom.
Emily WhittleNewcastle Genetics Laboratory, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom.
Ruby BarfordWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Alice LamparelliWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom.ORCID 0009-0006-5867-6072
Fiona HerdDepartment of Paediatric Oncology, Royal Aberdeen Children's Hospital, Aberdeen, Scotland, United Kingdom.
Katia MazzoccoDepartment of Pathology, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0002-6599-5681
Annalisa PezzoloMedical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0001-6321-5701
Martina MoriniLaboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0003-2569-4515
Martina ArditoLaboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0002-6008-9356
Alessandra EvaScientific Directorate, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Marzia OgnibeneMedical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0003-3698-9319
Matthias FischerDepartment of Experimental Paediatric Oncology, University Children's Hospital, Medical Faculty, University of Cologne, Cologne, Germany.ORCID 0000-0003-1363-1242
Sandra AckermannDepartment of Experimental Paediatric Oncology, University Children's Hospital, Medical Faculty, University of Cologne, Cologne, Germany.ORCID 0000-0002-5869-7344
Carolina RosswogDepartment of Experimental Paediatric Oncology, University Children's Hospital, Medical Faculty, University of Cologne, Cologne, Germany.ORCID 0000-0002-8855-6198
Barbara HeroDepartment of Pediatric Oncology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, Cologne, Germany.ORCID 0000-0003-4129-890X
Graham R SmithBioinformatics Support Unit, The Medical School, Newcastle University, Newcastle Upon Tyne, United Kingdom.ORCID 0000-0001-6967-7691
Adrienne A UnsworthBioinformatics Support Unit, The Medical School, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Michael McCorkindaleBioinformatics Support Unit, The Medical School, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Sally L GeorgeDivision of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-2777-4922
Jennifer TallDivision of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.
Jan J MolenaarPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Yvette MatserPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-7182-3202
Karin LangenbergPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-6780-0585
Godelieve TytgatPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0003-4452-0748
Rosa NogueraDepartment of Pathology, Medical School, University of Valencia-Incliva Health Research Institute/CIBERONC, Madrid, Spain.
Ana P BerbegallDepartment of Pathology, Medical School, University of Valencia-Incliva Health Research Institute/CIBERONC, Madrid, Spain.ORCID 0000-0002-8798-3286
Jaime Font de MoraClinical and Translational Research in Cancer, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.ORCID 0000-0002-6816-2095
Valérie CombaretLaboratoire de Recherche Translationnelle, Centre Léon-Bérard, Lyon, Auvergne-Rhone-Alpes, France.
Gaelle PierronUnité de Génétique Somatique, Institut Curie, Paris, France.ORCID 0000-0002-2536-7680
Annick Mühlethaler-MottetPediatric Hematology-Oncology Research Laboratory, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-8274-0907
Jacqueline SchoumansOncogenomics Laboratory, Hematology Service, Department of Laboratory Medicine and Pathology, University Hospital CHUV, Lausanne, Switzerland.
Joëlle TchindaUniversity Children's Hospital Zurich, Oncology Laboratory, Zurich, Switzerland.
Irina BanzolaSPHO Biobank Network, University Children's Hospital Zurich, Oncology Department, Zurich, Switzerland.
Marta JeisonSchneider Children's Medical Center of Israel, Petah Tikva, Israel.
Michal Hameiri-GrossmanSchneider Children's Medical Center of Israel, Petah Tikva, Israel.
Klaus H BeiskeDepartment of Pathology, Oslo University Hospital, Medical Faculty, University of Oslo, Oslo, Norway.ORCID 0000-0002-7772-7748
Nathalie AugerLaboratoire de Cytogénétique, Gustave Roussy, Villejuif, France.ORCID 0000-0002-9744-4470
Nadine Van RoyCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Nermine O BastaPopulation Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom.ORCID 0009-0003-0721-5557
Richard J Q McNallyPopulation Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom.ORCID 0000-0001-6685-6467
Sabine Taschner-MandlSt Anna Children's Cancer Research Institute, Vienna, Austria.ORCID 0000-0002-1439-5301
Vassilios PapadakisDepartment of Paediatric Haematology and Oncology (TAO), Marianna V Vardinoyannis-ELPIDA Oncology Hospital, Agia Sofia Children's Hospital, Athens, Greece.ORCID 0000-0002-1821-7799
Andrea Di CataldoDepartment of Clinical and Experimental Medicine, Unit of Paediatric Haematology and Oncology, University Policlinico, Catania, Italy.ORCID 0000-0002-4509-3066
Kate WheelerDepartment of Paediatric Oncology, Oxford Children's Hospital, Oxford, United Kingdom.
Jose D BermúdezDepartment of Statistics, University of Valencia, Valencia, Spain.ORCID 0000-0003-4699-5923
Maja Beck-PopovicUnit of Pediatric Hematology-Oncology, University Hospital CHUV, Lausanne, Switzerland.ORCID 0000-0001-9502-5697
Vanessa SeguraClinical and Translational Research in Cancer Group, Paediatric Oncology, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.ORCID 0000-0002-0410-9674
Adela CanetePaediatric Oncology Unit, Hospital Universitario y Politecnico La Fe and POG Department, University of Valencia, Valencia, Spain.
Gudrun SchleiermacherSIREDO Integrated Pediatric Oncology Center and Translational Research in Pediatric Oncology, U1330, INSERM, Institut Curie, Paris, France.ORCID 0000-0002-0133-5879
Deborah A TweddleWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, United Kingdom.ORCID 0000-0003-2208-3970
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntermediate-risk neuroblastoma patients older than 18 months, with non-
methodsWe conducted a large, international study including chromosomal copy number in all cases, next-generation DNA sequencing in most, and telomere maintenance mechanisms and gene expression in a subset, and correlated results with patient survival.
resultsAmong 98 tumors, 9/98 (9.2%) had oncogene amplifications (
conclusionOncogene amplification and/or p53 pathway abnormalities and/or typical SCAs identify patients with intermediate-risk neuroblastoma with inferior outcome for whom intensified or alternative treatments should be considered.
Indexed as
NeuroblastomaChild, PreschoolChromosome AberrationsFemaleGene AmplificationHumansInfantMalePrognosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.